Author Archives: Scalper1

Zendesk Stock Rises On Q4 Top-Line Beat, Keeps Adding Customers

Zendesk ( ZEN ) stock rose Wednesday after the cloud software vendor late Tuesday posted Q4 results that beat on the top line and met on the bottom line. The company reported Q4 revenue of $62.6 million, up 63% year over year and topping the consensus estimate of $60 million. It reported a per-share loss of 7 cents, matching the consensus estimate, as polled by Thomson Reuters. It reported a per-share loss of 11 cents in the year earlier quarter. Zendesk provides a cloud-based customer service software platform used primarily by small- to medium-size businesses. Its competitors include cloud software pioneer Salesforce.com ( CRM ), the leading maker of customer relationship management software. Zendesk stock was up 6%, near 17, in afternoon trading in the stock market today . Its shares, along with those of Salesforce.com and other enterprise software makers, tumbled on Feb. 5 after weak guidance by Tableau Software ( DATA ) raised fears of slower tech spending. Salesforce.com stock was up 5.5% Wednesday afternoon, and Tableau stock was up 3.5%. Zendesk finished Q4 with more than 69,000 customer accounts, up 7.8% from 64,000 in Q3. The company has a goal to reach $1 billion in revenue in 2020. “We are aggressively developing products and markets that move us beyond our core in customer support and into emerging opportunities around customer relationships.” Zendesk CEO Mikkel Svane said in the company’s earnings release. In November, Zendesk announced a partnership with Microsoft ( MSFT ), integrating its software with Microsoft Office 365. It was the first customer-service add-in for Microsoft Outlook, which is part of the Office 365 suite. Zendesk also is working with Facebook ( FB ) to add Facebook Messenger to its suite of applications. It would enable call centers to use Facebook Messenger to communicate with customers and prospects. Facebook Messenger could add $100 million in revenue, estimates Brendan Barnicle, an analyst at Pacific Crest Securities. Barnicle maintained an overweight rating on Zendesk and a price target of 35. Ross MacMillan, an analyst at RBC Capital Markets, maintained an outperform rating on Zendesk and a price target of 27. Zendesk expects Q1 revenue of $65 million to $67 million. The midpoint would be up 66% from the year-ago quarter. It sees an operating loss of $8 million to $9 million. For 2016, Zendesk expects revenue of $290 million to $300 million, up 41% at the midpoint, and an operating loss of $28 million to $30 million.  

Priceline Eases Fears Of Global Travel Slowdown, As Did Rivals

Priceline ( PCLN ) stock surged Wednesday after the company reinforced recent statements from online travel rivals Expedia and TripAdvisor that the global economic slowdown was not having a big impact on its business. Priceline also posted Q4 earnings and revenue above Wall Street estimates. Its Q1 sales guidance met views, but its EPS outlook missed at the midpoint. The company said that it expects Q1 sales to rise 9% to 16%, where Wall Street estimates 12.5% growth. The company sees earnings per share ex items rising 10% to 18%, where analysts have modeled 18% growth, to $9.62. Q4 sales rose 9% from the year-earlier quarter to $2 billion, modestly beating Wall Street’s expectations of $1.95 billion. But, as in some past quarters, Priceline’s earnings shattered expectations. The company posted earnings per share minus items of $12.63, up 16% and 83 cents above the consensus estimate of $11.80 by analysts polled by Thomson Reuters. Priceline stock gapped up more than 12% at the open on the stock market today and was up 11%, near 1,235, in afternoon trading Wednesday. Shares have recouped nearly all their losses in the tough 2016. Priceline has an IBD Composite Rating of 77, where 99 is the highest. Expedia stock was up 5% in afternoon trading Wednesday, while TripAdvisor was up 3%. Priceline’s Q4 earnings are hot off the heels of rivals Expedia ( EXPE ) and TripAdvisor ( TRIP ), which both reported last week. TripAdvisor with Q4 EPS and sales that beat expectations, and Expedia with its executives’ comments, eased fears that a slowing global economy was hurting the online travel industry. And in their Q4 earnings conference call, Expedia executives said that currency would be less of  a factor. Priceline’s $12 billion in Q4 also beat analyst estimates. RBC Capital Markets analyst Mark Mahaney said that lower airline fares — thanks to lower oil prices — and lower foreign exchange costs helped travel. Mahaney reiterated his outperform rating on Priceline stock, with a 1,700 price target. On the company’s Q4 earnings conference call with analysts, Priceline CEO Darren Huston praised his workforce. “Being a leader on online travel and building an experienced marketplace isn’t achieved by simply electronically connecting demand with supply,” Huston said on the call. “It may be a surprise to some, but about two-thirds of our employees are working in either the supply or customer service organizations. “The hard work of making this a daily reality is achieved by thousands of dedicated and energetic people around the world having these properties and then working with our partners on an ongoing basis to ensure that our customers have the most choices of places to stay at the best prices available.” Priceline’s ad costs, though, top personnel costs. The company said that its total personnel costs for Q4, including stock options, rose 14% to $312.8 million. The firm said that it spent $582 million on online advertising during the quarter, up 16% from $500 million in the year-earlier quarter. Analyst ‘More Positive’ About Priceline Outlook RBC is “incrementally more positive” on the stock, Mahaney wrote in a research note following the earnings release. He added that both growth and profitability remained strong. “We are more confident that Priceline will generate accelerating growth in 2016,” he wrote, “Thanks in part to foreign exchange stabilization, but also thanks in part to material new growth opportunities that Priceline has been investing in for years.” Mahaney reiterated his thesis from his earnings preview note that Chinese global travel, Latin America, business travel and alternative accommodations would drive Priceline growth. “Alternative accommodations” refers to hotel-like units available via the so-called “sharing economy.” San Francisco-based Airbnb is among the new breed of companies that lets people rent their homes, or just rooms in their homes, to travelers. Investors have valued the privately held Airbnb at more than $20 billion — though the Wall Street Journal and others have recently attacked such lofty valuations for failing to assess the value of shares properly. The WSJ reported that even sophisticated investors such as mutual funds have trouble accurately judging the value of such startups and have had to write down several investments from tech unicorns such as Dropbox and Uber. Priceline’s market valuation is near $64 billion, by far the highest among the 11 companies in IBD’s Leisure-Travel Booking industry group. No. 2 Expedia has a market cap under $17 billion. In the past, Mahaney has called Priceline “well hedged” against the fast rise of alternative accommodations providers such as Airbnb and Expedia-owed HomeAway. Though Expedia executives have said that alternative accommodations have not yet had a “material” impact on its bottom line, Expedia CEO Dara Khosrowshahi recently  told IBD that Airbnb has clearly “grown up” and that the brand has “clearly rung a bell for customers.”  

Bluebird Bio Starts First CAR-T Cancer Trial; Juno Gets An Upgrade

Biotech Bluebird Bio ( BLUE ) was trading up sharply Wednesday after the company said it started testing its cell therapy in blood cancer, triggering a $10 million payment from partner Celgene ( CELG ). And another Celgene partner, Juno Therapeutics, also was up Wednesday, after getting an upgrade. Last June, Bluebird and Celgene agreed to a three-year collaboration to develop Bluebird’s chimeric antigen receptor T cell (CAR-T) therapies targeting the B-cell maturation antigen (BCMA) to help the body fight cancer. On Wednesday, Bluebird said the first patient of its phase-one study of its candidate bb2121 in multiple myeloma had been treated, yielding a $10 million option-to-exercise payment from Celgene. Bluebird stock was up more than 7% in afternoon trading on the stock market today , near 54. “While Celgene’s opt-in decision doesn’t come entirely unexpected, we view the decision positively since it further validates Bluebird’s CAR-T effort,” wrote Leerink analyst Michael Schmidt in a research note. “While several other groups have been working on myeloma CAR-T programs, anti-BCMA CAR-T data from Bluebird’s collaborator at the NCI (National Cancer Institute) . . . has been most promising to date in our view.” Celgene’s lead drug Revlimid is currently one of the most popular treatments for multiple myeloma, but since it’s due to lose patent protection in a few years the company has been looking at newer technologies. Meanwhile, another Celgene partner in CAR-T, Juno Therapeutics ( JUNO ), got an upgrade from Guggenheim on Wednesday based on both valuation and a reassessment of its spending habits. “Juno has been steadily amassing an arsenal of tools to increase efficacy and reduce toxicity of T cell therapies,” wrote analyst Tony Butler as he upgraded the stock to buy from neutral and set the price target at 41. “It is a pay-me-now-or-pay-me-later scenario. . . . While not all of these investments may pay out in the future, it is likely that one or two will, and they could provide Juno the opportunity to surpass the competition or, at the very least, to stay at the vanguard of T cell therapies.” Juno stock was up more than 6.7% in afternoon trading, near 34.